Announcement on Subsidiary Obtaining Notice of Approval for Drug Clinical Trials
Release time:
2021-05-20
Securities Code: 600668 Securities Abbreviation: Jianfeng Group No: pro 2021-001
Zhejiang Jianfeng Group Co., Ltd.
Announcement on Subsidiaries Obtaining Drug Clinical Trial Approval Notice
The Board of Directors and all directors of the Company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and assumes individual and joint responsibility for the truthfulness, accuracy and completeness of its contents .
Important Note:
- Company's approval notice for drug clinical trials will not have a significant impact on the company's recent operating results.
- Risk Warning: Due to the particularity of drug research and development, the pre-development of drugs and the long cycle and many links of products from development, clinical trials to production are susceptible to some uncertain factors, clinical trial progress, There are many uncertainties in the results and the future product market competition situation.
1. Summary
Recently, Zhejiang Erying Pharmaceutical Co., Ltd. (hereinafter referred to as "Erying Company") and , the controlling subsidiary of Zhejiang Jianfeng Pharmaceutical Co., Ltd., the controlling subsidiary of the Company, received the Notice of Approval for Clinical Trials of Drugs approved and issued by the State Drug Administration. The relevant details are hereby announced as follows:
2. drug basic information content
drug name: acetaminophen suppository
English name: Paracetamol Suppositories
dosage form: suppository
application classification: generic drug application
specification: 75mg , 125mg
registration classification: chemical drugs category 3
applicant: Zhejiang erying drug co., ltd.
approval conclusion: "according to the the People's Republic of China drug administration law and relevant regulations, after examination, the acetaminophen suppository accepted on 2020 5 February 13 meets the relevant requirements for drug registration, it is recommended that the bioequivalence study of this product be carried out in healthy adults with a single fasting dose, and that the study of BE be exempted under different specifications to meet pharmaceutical requirements."
3. Drug Research and Development and Investment
Acetaminophen Suppository is an antipyretic analgesic developed by Erying Company. Its registered classification belongs to chemical drug 3 . Acetaminophen Suppository is indicated for fever caused by common cold or influenza in children, and is also used for relieving mild to moderate pain such as headache, arthralgia, migraine, toothache, myalgia and neuralgia. As of the date of this announcement, the accumulated research and development expenses and technical investment of the project totaled about RMB ,788.09 . Market Situation of
4. Similar Drugs
Acetaminophen Suppository was first developed by German Bene Company and listed in Germany in 1960 . In 2019 , the dosage of German acetaminophen Suppository was about 1.08 .6 billion tablets (data source: IMS ). At present, paracetamol suppositories of infant specifications have been listed in many countries in the world. At present, paracetamol suppositories of 125 mg , 150 mg , 300 mg and 600 mg have been listed in China, of which 125 mg and 150 mg are used for fever caused by common cold or influenza in children aged 1-6 , no paracetamol suppositories exist for infants and young children aged 0-1 years. Acetaminophen suppository (75 mg ) developed by Erying Company is suitable for antipyretic and analgesic treatment for infants aged 0-1 years old in China. Acetaminophen suppository (125 mg ) is suitable for infants aged 6 months to 2 years old (administered according to age and weight). Scientifically administered acetaminophen suppository will be provided for infants aged 0-2-2-116 years old. Approval Procedures to Be Performed for Listing of 5. Products
Er Ying Company will conduct clinical trials (bioequivalence studies) according to the requirements of the Notice of Approval of Drug Clinical Trials. After the clinical trials are completed, it will apply for production. After passing the review and approval of the State Food and Drug Administration and obtaining the approval documents for drug production, it can produce
products and go on sale. 6. Impact on Listed Companies and Risk Tips
The company's approval notice for drug clinical trials will not have a significant impact on the company's recent operating results. Due to the particularity of drug research and development, the pre-development of drugs and the long cycle and many links from development, clinical trials to production of products are easily affected by some uncertain factors. There are many uncertainties in the progress and results of clinical trials and the future product market competition situation. The company will be based on the progress of research and development in a timely manner to fulfill the obligations of information disclosure, so that the majority of investors pay attention to investment risks.
hereby announce
Zhejiang Jianfeng Group Co., Ltd. Board of Directors
January 6, 2001
More information
Shanghai Bronze Award for Outstanding Invention Went in North Carolina
News from this newspaper The results of the 31st Shanghai Excellent Invention Trial jointly organized by the Shanghai Federation of Trade Unions, Shanghai Intellectual Property Office, Shanghai Municipal Committee of the Communist Youth League, Shanghai Science and Technology Association, and Shanghai Invention Association were evaluated a few days ago. The "Quality Improvement and Industrialization Optimization of Erlotinib Hydrochloride and Its Advanced Intermediates" declared by Technology Co., Ltd. won the bronze award. Erlotinib hydrochloride is a targeted therapy drug for the treatment of non-small cell lung cancer, which can prolong the survival time and improve the quality of life of lung cancer patients. It can target and specific sites of action to kill tumor cells, and has little impact on normal tissues. It belongs to the biological and new medical technology in the field of high-tech supported by the state. In this invention, 6,7-dimethoxyquinazoline -4-one, 4-chloro -6,7-di (2-methoxyethoxy) quinazoline and 3-aminophenylacetylene are important intermediates of erlotinib hydrochloride, which is also an important intermediate of icotinib hydrochloride, the first new anti-tumor drug of tinib in China. The invention designs and adopts a new synthesis process route, which can effectively reduce the cost of raw materials, the reactions are mostly aqueous phase reactions, energy consumption and three waste emissions are reduced by about 35%, industrialization conditions are optimized, product quality is improved, and it is applied to Industrialized mass production is conducive to the production of high-quality and low-cost erlotinib hydrochloride drugs and reduces the economic burden of patients. The Shanghai Excellent Invention Trial was founded in 1987. It is an important science and technology award approved by the Shanghai Municipal Government. It not only strongly promoted the majority of employees to carry out invention and creation activities based on their posts, but also improved the order.
2020
07-31
Jiang Xiaomeng was selected as one of the top ten news figures in the building materials industry. "China Building Materials" magazine published an exclusive interview in August. The 8th issue of 2019 "China Building Materials" magazine published a few days ago. In the "Exclusive Perspective" column, it published an exclusive interview with Jiang Xiaomeng, the top ten news figures in the building materials industry in 2018, the party secretary and chairman of the group company. The selection of the top ten news figures in the national building materials industry initiated by "China Building Materials" magazine has established nearly a hundred shining figures in the industry since 1999, which has attracted widespread attention in the industry. The selection of the top ten news figures in the building materials industry in 2018 is described as follows: Jiang Xiaomeng is a scholar and practical outstanding entrepreneur. In 2018, with his strategic thinking of insight into the future, he united and led cadres and employees at all levels of Jianfeng Group to actively adapt to the new economic normal, focusing on deepening supply-side structural reforms, the "Belt and Road" initiative, and vigorously advocating corporate transformation and upgrading and high-quality development. Work, seize opportunities, reform and innovate, and achieve historic new achievements in the development of the peak 60 years. The group's overall economic efficiency and development quality have been significantly improved. In recent years, under the leadership of Jiang Xiaomeng, Jianfeng Group has seized the opportunity to join forces with central enterprises to participate in the establishment of Southern Cement, effectively integrate the cement market in Zhejiang Province, optimize the allocation of cement industry resources, and greatly improve social and economic benefits. It has a positive and far-reaching impact on the supply-side structural reform and healthy development of the cement industry in Zhejiang Province. At the same time, the long-term layout of the peak group, strategically predict the direction of national development.
2020
07-31
Jianfeng Group started from a small cement plant with an annual output of 30000 tons in 1958. Through horizontal alliance with township enterprises, the formation of enterprise groups and the implementation of joint-stock reform, Jianfeng Group took the lead in listing in China's cement industry in 1993 and explored diversified operation. In 2007, Jianfeng joined hands with the central enterprise China Building Materials to participate in the establishment of Southern Cement, which strategically shifted the focus of the cement industry, and at the same time through enterprise mergers and technological innovation, the pharmaceutical industry is growing rapidly ...... Such a long history, in the industry has a good reputation of enterprises, Zhejiang Province, the earliest existing listed companies, its head is Jiang Xiaomeng. Focus on Industry Jiang Xiaomeng has spent nearly 40 years in Jinhua Cement Factory, the predecessor of Jianfeng Group. As a witness and promoter of the development and growth of the peak, Jiang Xiaomeng said that the sustained and steady development of the peak group benefits from the long-term focus on industry, which is the value orientation of the peak and the responsibility of the enterprise. Whether there was only a single cement industry in the early stage or the diversified development after listing, all the investment projects of the peak have not left the industry. With the continuous emergence of new economic formats, many people once suggested that the peak should be transferred to the "fashionable" and rewarding industries such as the Internet, but they were all rejected. Jiang Xiaomeng explained that it is necessary to use professional people to do professional things. Peak's years of experience, talents, and resource accumulation are all in industry. Although the new format is good, it is not necessarily suitable for peak development. Take cement as an example, even in the case of peak pharmaceutical has occupied the group.
2020
07-31
Jiang Xiaomeng was selected as one of the top ten news figures in the building materials industry. "China Building Materials" magazine published an exclusive interview in August. The 8th issue of 2019 "China Building Materials" magazine published a few days ago. In the "Exclusive Perspective" column, it published an exclusive interview with Jiang Xiaomeng, the top ten news figures in the building materials industry in 2018, the party secretary and chairman of the group company. The selection of the top ten news figures in the national building materials industry initiated by "China Building Materials" magazine has established nearly a hundred shining figures in the industry since 1999, which has attracted widespread attention in the industry. The selection of the top ten news figures in the building materials industry in 2018 is described as follows: Jiang Xiaomeng is a scholar and practical outstanding entrepreneur. In 2018, with his strategic thinking of insight into the future, he united and led cadres and employees at all levels of Jianfeng Group to actively adapt to the new economic normal, focusing on deepening supply-side structural reforms, the "Belt and Road" initiative, and vigorously advocating corporate transformation and upgrading and high-quality development. Work, seize opportunities, reform and innovate, and achieve historic new achievements in the development of the peak 60 years. The group's overall economic efficiency and development quality have been significantly improved. In recent years, under the leadership of Jiang Xiaomeng, Jianfeng Group has seized the opportunity to join forces with central enterprises to participate in the establishment of Southern Cement, effectively integrate the cement market in Zhejiang Province, optimize the allocation of cement industry resources, and greatly improve social and economic benefits. It has a positive and far-reaching impact on the supply-side structural reform and healthy development of the cement industry in Zhejiang Province. At the same time, the long-term layout of the peak group, strategically predict the direction of national development.
2020
07-31
Jiang Xiaomeng was selected as one of the top ten news figures in the building materials industry. "China Building Materials" magazine published an exclusive interview in August. The 8th issue of 2019 "China Building Materials" magazine published a few days ago. In the "Exclusive Perspective" column, it published an exclusive interview with Jiang Xiaomeng, the top ten news figures in the building materials industry in 2018, the party secretary and chairman of the group company. The selection of the top ten news figures in the national building materials industry initiated by "China Building Materials" magazine has established nearly a hundred shining figures in the industry since 1999, which has attracted widespread attention in the industry. The selection of the top ten news figures in the building materials industry in 2018 is described as follows: Jiang Xiaomeng is a scholar and practical outstanding entrepreneur. In 2018, with his strategic thinking of insight into the future, he united and led cadres and employees at all levels of Jianfeng Group to actively adapt to the new economic normal, focusing on deepening supply-side structural reforms, the "Belt and Road" initiative, and vigorously advocating corporate transformation and upgrading and high-quality development. Work, seize opportunities, reform and innovate, and achieve historic new achievements in the development of the peak 60 years. The group's overall economic efficiency and development quality have been significantly improved. In recent years, under the leadership of Jiang Xiaomeng, Jianfeng Group has seized the opportunity to join forces with central enterprises to participate in the establishment of Southern Cement, effectively integrate the cement market in Zhejiang Province, optimize the allocation of cement industry resources, and greatly improve social and economic benefits. It has a positive and far-reaching impact on the supply-side structural reform and healthy development of the cement industry in Zhejiang Province. At the same time, the long-term layout of the peak group, strategically predict the direction of national development.
2020
07-30
On August 29, the group company held the 11th meeting of the 10th board of directors of the company by means of communication, and deliberated and passed the semi annual report of Jianfeng group in 2019 and the amendment of internal control system of the company. In the first half of the year, the company focused on the general work policy of "innovation and reform, integration and improvement, scientific layout, and steady development", grasping the opportunities brought by economic structure optimization and industrial upgrading externally, continuously integrating resources internally, and improving the internal management system. Improve the efficiency of enterprise operation. In the first half of 2019, the company achieved total operating income of 1.686 billion billion yuan, an increase of 12.17 percent over the same period last year, and the net profit attributable to the owners of the parent company was 0.476 billion billion yuan, an increase of 57.55 percent over the same period last year. At the end of June 2019, the Company's total assets were $5.383 billion, up 9.82 from the beginning of the year, and its net assets were $3.817 billion, up 10.64 from the beginning of the year. In the first half of the year, the company made a new breakthrough in the expansion of cement business. The group company has completed the acquisition of 100 equity of Guizhou huangpinggu longmingchuan cement co., ltd. and continues to invest in the construction of its new dry cement production line with a daily output of 4500 tons of cement clinker (with waste heat power generation). Yunnan Jianfeng invested 5 million yuan to participate in the establishment of Yunnan Jianfeng Da Zhan Cement Co., Ltd., which plans to build a cement clinker production line in lameng county, Xishuangxian Dai autonomous prefecture by capacity replacement according to relevant national policies. The company's cement subsidiaries continue to carry out in-depth "three down three improve" activities, stable.
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page